Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Therapeutic Drug Carrier Systems
Factor de Impacto: 2.9 Factor de Impacto de 5 años: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Imprimir: 0743-4863
ISSN En Línea: 2162-660X

Volumen 36, 2019 Volumen 35, 2018 Volumen 34, 2017 Volumen 33, 2016 Volumen 32, 2015 Volumen 31, 2014 Volumen 30, 2013 Volumen 29, 2012 Volumen 28, 2011 Volumen 27, 2010 Volumen 26, 2009 Volumen 25, 2008 Volumen 24, 2007 Volumen 23, 2006 Volumen 22, 2005 Volumen 21, 2004 Volumen 20, 2003 Volumen 19, 2002 Volumen 18, 2001 Volumen 17, 2000 Volumen 16, 1999 Volumen 15, 1998 Volumen 14, 1997 Volumen 13, 1996 Volumen 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v12.i2-3.30
pages 233-261

Liposome-Mediated Drug Targeting in Topical and Regional Therapies

Rimona Margalit
Department of Biochemistry, Tel Aviv University, Tel Aviv 69978, Israel


Liposome-mediated drug targeting is reviewed in four major categories of topical and regional therapies: wounds and burns, ocular, intraperitoneal, and pulmonary. A survey of the data in the field is preceded by definitions of carrier-mediated drug targeting, in particular for topical and regional treatments. The ability of liposomes to meet essential requirements for task performance and liposome surface-modification as the major approach to endow liposomes with targeting abilities are reviewed. Analysis of current findings in the field shows that (1) most studies explored regular liposomes that were unable to meet the essential requirements for targeting and (2) in vivo drug targeting in topical and regional therapies has been achieved rarely and seldom attempted, yet there are encouraging indications from a few studies that using surface-modified liposomes such targeting is feasible. Both established and novel liposomal systems attest to this feasibility and point out future directions. The former can be found by revisiting immunoliposomes that were initially designed for systemic administration but might well fit topical and regional cases. The latter is exemplified by bioadhesive liposomes, designed specifically for topical/regional therapies. It is concluded that careful implementation of such approaches could be successful for the achievement of liposome-mediated drug targeting in topical and regional therapies.